OBJECTIVES: To investigate the crucial role of miR-26a in breast cancer and to validate whether miR-26a could regulate proliferation of breast cancer cells by targeting high mobility group AT-hook 1 (HMGA1). METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression levels of miR-26a in breast cancer and adjacent non-cancerous breast tissues. MTT, cell migration and invasion assay were carried out to characterize the miR-26a function. Finally, to validate the target gene of miR-26a, luciferase reporter assay was employed, followed by RT-PCR and Western blot confirmation. RESULTS: Compared with normal tissues, a significant down-regulation of miR-26a expression was observed in breast cancer tissues (P=0.002). miR-26a suppresses MDA-MB-231 and Mcf-7 breast cancer cell lines proliferation and motility. The luciferase activity was significantly decreased after co-transfection with psiCHECK-2/HMGA1 3'-UTR and miR-26a mimics in comparison with control cells, and qRT-PCR and Western blotting analysis found that HMGA1 expression at the mRNA and protein levels decreased in the miR-26a mimic-treatment group relative to NC. MTT assay showed that down regulation of HMGA1 by siRNA could significantly enhance the tumor-suppressive effect of miR-26a (P < 0.05). CONCLUSIONS: The results of the present study indicate that miR-26a may be associated with human breast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1.
OBJECTIVES: To investigate the crucial role of miR-26a in breast cancer and to validate whether miR-26a could regulate proliferation of breast cancer cells by targeting high mobility group AT-hook 1 (HMGA1). METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was used to quantify the expression levels of miR-26a in breast cancer and adjacent non-cancerous breast tissues. MTT, cell migration and invasion assay were carried out to characterize the miR-26a function. Finally, to validate the target gene of miR-26a, luciferase reporter assay was employed, followed by RT-PCR and Western blot confirmation. RESULTS: Compared with normal tissues, a significant down-regulation of miR-26a expression was observed in breast cancer tissues (P=0.002). miR-26a suppresses MDA-MB-231 and Mcf-7 breast cancer cell lines proliferation and motility. The luciferase activity was significantly decreased after co-transfection with psiCHECK-2/HMGA1 3'-UTR and miR-26a mimics in comparison with control cells, and qRT-PCR and Western blotting analysis found that HMGA1 expression at the mRNA and protein levels decreased in the miR-26a mimic-treatment group relative to NC. MTT assay showed that down regulation of HMGA1 by siRNA could significantly enhance the tumor-suppressive effect of miR-26a (P < 0.05). CONCLUSIONS: The results of the present study indicate that miR-26a may be associated with humanbreast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1.
Entities:
Keywords:
Breast cancer; HMGA1; miR-26a; proliferation
Authors: Jason T Huse; Cameron Brennan; Dolores Hambardzumyan; Boyoung Wee; John Pena; Sara H Rouhanifard; Cherin Sohn-Lee; Carlos le Sage; Reuven Agami; Thomas Tuschl; Eric C Holland Journal: Genes Dev Date: 2009-06-01 Impact factor: 11.361
Authors: Li Yu; Juan Lu; Bao Zhang; Xiong Liu; Lu Wang; Si-Yang Li; Xiao-Hong Peng; Xia Xu; Wen-Dong Tian; Xiang-Ping Li Journal: Oncol Lett Date: 2013-02-04 Impact factor: 2.967
Authors: Debashree Basudhar; Gaurav Bharadwaj; Veena Somasundaram; Robert Y S Cheng; Lisa A Ridnour; Mayumi Fujita; Stephen J Lockett; Stephen K Anderson; Daniel W McVicar; David A Wink Journal: Br J Pharmacol Date: 2018-11-06 Impact factor: 8.739
Authors: E P Bastos; H Brentani; C A B Pereira; A Polpo; L Lima; R D Puga; F S Pasini; C A B T Osorio; R A Roela; M I Achatz; A P Trapé; A M Gonzalez-Angulo; M M Brentani Journal: PLoS One Date: 2016-05-06 Impact factor: 3.240